ArticlebioRxiv : the preprint server for biology2026
Prioritizing peptides for targeted mass spectrometry experiments using deep learning.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
One critical step in any targeted mass spectrometry experiment is selecting, from each protein of interest, a small number of peptides that respond well in the mass spectrometer and can serve as reliable proxies for protein quantification. Existing methods select target peptides either by relying on prior empirical measurements, limiting their applicability to previously observed peptides, or using machine learning to predict peptide behavior from sequence alone. However, current machine learning tools suffer from various limitations, including using detectability as an indirect proxy for intensity, relying on small training sets, or ignoring the precursor charge state. In this study, we introduce Bromo, a transformer-based deep learning model that ranks peptide precursors from a given protein by their relative response, taking charge state into account. Trained on millions of annotated peptide pairs derived from large-scale, publicly available data-independent acquisition mass spectrometry data, Bromo consistently outperforms existing sequence-based methods across diverse, independent datasets. Furthermore, we show that finetuning Bromo on experiment-specific data can account for differences in sample preparation, sample matrix, and instrument platform, all of which influence which peptides serve as optimal targets. This adaptability makes Bromo a practical tool for selecting target peptides for selected reaction monitoring and parallel reaction monitoring assay development across a wide range of experimental conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.